{"transactions":[{"id":724142,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-29T20:31:40.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":2417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":2417,"derivative":{"underlying":"Common Stock","underlying_shares":2417},"source":{"system":"sec-edgar","filing":"0001662426-26-000006","document":"wk-form4_1782765098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242626000006/wk-form4_1782765098.xml","form_type":"4"}},{"id":724141,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:31:40.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":3837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":3837,"derivative":{"exercise_price":64.34,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":3837},"source":{"system":"sec-edgar","filing":"0001662426-26-000006","document":"wk-form4_1782765098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242626000006/wk-form4_1782765098.xml","form_type":"4"}},{"id":730003,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-06-22T20:08:22.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":22371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":56904,"source":{"system":"sec-edgar","filing":"0000905148-26-003030","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000090514826003030/form4.xml","form_type":"4"}},{"id":731644,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2026-06-18T20:32:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":30.57,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-26-000261","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000161071726000261/form4.xml","form_type":"4"}},{"id":736355,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-16T20:06:49.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":2954,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2954},"source":{"system":"sec-edgar","filing":"0001662426-26-000004","document":"wk-form4_1781640402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242626000004/wk-form4_1781640402.xml","form_type":"4"}},{"id":736354,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:06:49.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":2954,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":7638,"source":{"system":"sec-edgar","filing":"0001662426-26-000004","document":"wk-form4_1781640402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242626000004/wk-form4_1781640402.xml","form_type":"4"}},{"id":763212,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:24:18.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001662426-26-000002","document":"form4-05262026_080514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000166242626000002/form4-05262026_080514.xml","form_type":"4"}},{"id":1039410,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-09-16T20:06:27.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1334},"source":{"system":"sec-edgar","filing":"0001662426-25-000005","document":"wk-form4_1758053184.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242625000005/wk-form4_1758053184.xml","form_type":"4"}},{"id":1039409,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:06:27.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":4684,"source":{"system":"sec-edgar","filing":"0001662426-25-000005","document":"wk-form4_1758053184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000166242625000005/wk-form4_1758053184.xml","form_type":"4"}},{"id":1100799,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T20:55:36.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":21.78,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-25-000262","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000161071725000262/form4.xml","form_type":"4"}},{"id":1103436,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2025-06-23T20:11:20.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":10831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":34533,"source":{"system":"sec-edgar","filing":"0000905148-25-002218","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000090514825002218/form4.xml","form_type":"4"}},{"id":1109408,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:27:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000231","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071725000231/form4.xml","form_type":"4"}},{"id":1109884,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-16T20:04:12.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":3350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3350},"source":{"system":"sec-edgar","filing":"0001819790-25-000090","document":"wk-form4_1750104245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000090/wk-form4_1750104245.xml","form_type":"4"}},{"id":1109883,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-16T20:04:12.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":2954,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":2954,"derivative":{"underlying":"Common Stock","underlying_shares":2954},"source":{"system":"sec-edgar","filing":"0001819790-25-000090","document":"wk-form4_1750104245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000090/wk-form4_1750104245.xml","form_type":"4"}},{"id":1109882,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-16T20:04:12.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":4540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":4540,"derivative":{"exercise_price":40.95,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":4540},"source":{"system":"sec-edgar","filing":"0001819790-25-000090","document":"wk-form4_1750104245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000090/wk-form4_1750104245.xml","form_type":"4"}},{"id":1109881,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:04:12.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":3350,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":3350,"source":{"system":"sec-edgar","filing":"0001819790-25-000090","document":"wk-form4_1750104245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000090/wk-form4_1750104245.xml","form_type":"4"}},{"id":1144727,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:06:33.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013412","document":"form4-05162025_080528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000141588925013412/form4-05162025_080528.xml","form_type":"4"}},{"id":1150374,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2025-05-13T20:48:29.000Z","date":"2025-05-09","kind":"sale","planned":false,"acquired":false,"shares":23799,"price":30.0469,"value":715086.1731,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects a weighted average sale price of $30.0469 per share, at prices ranging from $30.01 to $30.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":23702,"source":{"system":"sec-edgar","filing":"0000905148-25-001598","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000090514825001598/form4.xml","form_type":"4"}},{"id":1394663,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T21:27:04.000Z","date":"2024-09-30","kind":"gift","planned":false,"acquired":false,"shares":6016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust for no consideration. The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001819790-24-000115","document":"wk-form4_1727904418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000115/wk-form4_1727904418.xml","form_type":"4"}},{"id":1405289,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-09-17T21:52:10.000Z","date":"2024-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."}],"balance_after":1334,"derivative":{"underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001819790-24-000113","document":"wk-form4_1726609924.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000113/wk-form4_1726609924.xml","form_type":"4"}},{"id":1405288,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T21:52:10.000Z","date":"2024-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":6016,"source":{"system":"sec-edgar","filing":"0001819790-24-000113","document":"wk-form4_1726609924.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000113/wk-form4_1726609924.xml","form_type":"4"}},{"id":1469600,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T22:23:11.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":false,"shares":3350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3350},"source":{"system":"sec-edgar","filing":"0001819790-24-000099","document":"wk-form4_1719354184.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000099/wk-form4_1719354184.xml","form_type":"4"}},{"id":1469599,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T22:23:11.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":true,"shares":3350,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":4683,"source":{"system":"sec-edgar","filing":"0001819790-24-000099","document":"wk-form4_1719354184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000099/wk-form4_1719354184.xml","form_type":"4"}},{"id":1472739,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"American Depositary Shares","published_at":"2024-06-20T21:00:33.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":21253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date."}],"balance_after":47501,"source":{"system":"sec-edgar","filing":"0000905148-24-001749","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000090514824001749/form4.xml","form_type":"4"}},{"id":1476837,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:44:55.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000342","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071724000342/form4.xml","form_type":"4"}},{"id":1479226,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-14T21:30:40.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":3350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":3350,"derivative":{"underlying":"Common Stock","underlying_shares":3350},"source":{"system":"sec-edgar","filing":"0001819790-24-000075","document":"wk-form4_1718400631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000075/wk-form4_1718400631.xml","form_type":"4"}},{"id":1479225,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T21:30:40.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":5000,"derivative":{"exercise_price":33.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001819790-24-000075","document":"wk-form4_1718400631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000075/wk-form4_1718400631.xml","form_type":"4"}},{"id":1496294,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:38:19.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":36.55,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-24-000275","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000161071724000275/form4.xml","form_type":"4"}},{"id":1510381,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-17T20:15:53.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":42.69,"expiration_date":"2034-05-14","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-24-013490","document":"form4-05172024_080541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000141588924013490/form4-05172024_080541.xml","form_type":"4"}},{"id":1717432,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:03:53.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000388","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071723000388/form4.xml","form_type":"4"}},{"id":1777437,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-09-19T20:25:56.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."}],"balance_after":2667,"derivative":{"underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001819790-23-000075","document":"wk-form4_1695155145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000075/wk-form4_1695155145.xml","form_type":"4"}},{"id":1777436,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T20:25:56.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":1333,"source":{"system":"sec-edgar","filing":"0001819790-23-000075","document":"wk-form4_1695155145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000075/wk-form4_1695155145.xml","form_type":"4"}},{"id":1840788,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2023-06-30T20:17:31.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":18903,"price":26.45,"value":499984.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs."}],"balance_after":26248,"source":{"system":"sec-edgar","filing":"0000950170-23-031116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000095017023031116/ownership.xml","form_type":"4"}},{"id":1844314,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-26T21:45:28.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":3350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":3350,"derivative":{"underlying":"Common Stock","underlying_shares":3350},"source":{"system":"sec-edgar","filing":"0001819790-23-000052","document":"wk-form4_1687815920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000052/wk-form4_1687815920.xml","form_type":"4"}},{"id":1844313,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T21:45:28.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":5000,"derivative":{"exercise_price":17.99,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001819790-23-000052","document":"wk-form4_1687815920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000052/wk-form4_1687815920.xml","form_type":"4"}},{"id":1848739,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:59:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000186","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000161071723000186/form4.xml","form_type":"4"}},{"id":1860003,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:45:32.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":25.4,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-23-000112","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000161071723000112/form4.xml","form_type":"4"}},{"id":1894648,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-12T20:16:10.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":20000,"derivative":{"exercise_price":7.7,"expiration_date":"2033-05-09","underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-029031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000120919123029031/doc4.xml","form_type":"4"}},{"id":2139309,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-11T20:23:55.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in three equal annual installments on September 15th of each of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in three equal annual installments on September 15th of each of 2023, 2024, and 2025, subject to the Reporting Person's continuous service."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001628280-22-026246","document":"wf-form4_166551982032663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000162828022026246/wf-form4_166551982032663.xml","form_type":"4"}},{"id":2139308,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-10-11T20:23:55.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares vest in three equal annual installments beginning on October 6, 2023, subject to the Reporting Person's continuous service."}],"balance_after":14000,"derivative":{"exercise_price":17.21,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001628280-22-026246","document":"wf-form4_166551982032663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000162828022026246/wf-form4_166551982032663.xml","form_type":"4"}},{"id":2141043,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":22.3,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141042,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":37.09,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141041,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5247,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":64.75,"underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141040,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":56.3,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141039,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":42.25,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141038,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.45,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141037,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":18.85,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141036,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.21,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141035,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit of the Issuer (\"RSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2141034,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T16:20:56.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":6637,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033163/doc4.xml","form_type":"4"}},{"id":2185291,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-15T22:39:12.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.965,"expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-016294","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761922016294/doc1.xml","form_type":"4"}},{"id":2226602,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-18T01:31:44.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.9899,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013140","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761922013140/doc1.xml","form_type":"4"}},{"id":2229447,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T18:00:48.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322022888/doc4.xml","form_type":"4"}},{"id":2229446,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T18:00:48.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":22.3,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-022888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322022888/doc4.xml","form_type":"4"}},{"id":2229445,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T18:00:48.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."}],"balance_after":0,"derivative":{"exercise_date":"2022-06-14","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322022888/doc4.xml","form_type":"4"}},{"id":2229444,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T18:00:48.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6637,"source":{"system":"sec-edgar","filing":"0000899243-22-022888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322022888/doc4.xml","form_type":"4"}},{"id":2235307,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T22:23:42.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.29,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-22-012697","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000156761922012697/doc1.xml","form_type":"4"}},{"id":2254854,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T20:09:10.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":9925,"derivative":{"exercise_price":16.14,"expiration_date":"2032-05-23","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0001209191-22-032168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000120919122032168/doc4.xml","form_type":"4"}},{"id":2540201,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-10-18T12:20:54.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":7345,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7345,"source":{"system":"sec-edgar","filing":"0000899243-21-040423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000089924321040423/doc4.xml","form_type":"4"}},{"id":2571689,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-13T20:51:22.000Z","date":"2021-09-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.6,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-017008","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761921017008/doc1.xml","form_type":"4"}},{"id":2572885,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-10T20:00:17.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":4800,"price":30.2089,"value":145002.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold ranging from $30.1800 to $30.2850 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3037,"source":{"system":"sec-edgar","filing":"0000899243-21-035590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321035590/doc4.xml","form_type":"4"}},{"id":2659960,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T16:14:44.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-21-024967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321024967/doc4.xml","form_type":"4"}},{"id":2659959,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T16:14:44.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":37.09,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-21-024967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321024967/doc4.xml","form_type":"4"}},{"id":2659958,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T16:14:44.000Z","date":"2021-06-17","kind":"exercise","acquired":false,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-17","underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-21-024967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321024967/doc4.xml","form_type":"4"}},{"id":2659957,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T16:14:44.000Z","date":"2021-06-17","kind":"exercise","acquired":true,"shares":3037,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":7837,"source":{"system":"sec-edgar","filing":"0000899243-21-024967","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321024967/doc4.xml","form_type":"4"}},{"id":2665458,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T21:04:15.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":21.66,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-21-012205","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000156761921012205/doc1.xml","form_type":"4"}},{"id":2665507,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-16T20:17:17.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-012193","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761921012193/doc1.xml","form_type":"4"}},{"id":2709872,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T00:41:19.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders."}],"balance_after":9925,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0001209191-21-033349","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000120919121033349/doc4.xml","form_type":"4"}},{"id":3103897,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:32:24.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3037,"derivative":{"underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-20-017317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320017317/doc4.xml","form_type":"4"}},{"id":3103896,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T21:32:24.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":5247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5247,"derivative":{"exercise_price":64.75,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-20-017317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320017317/doc4.xml","form_type":"4"}},{"id":3103895,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:32:24.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-20-017317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320017317/doc4.xml","form_type":"4"}},{"id":3103894,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-19T21:32:24.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4800,"source":{"system":"sec-edgar","filing":"0000899243-20-017317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320017317/doc4.xml","form_type":"4"}},{"id":3105029,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:44:01.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.84,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-20-012377","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000156761920012377/doc1.xml","form_type":"4"}},{"id":3111413,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T21:14:23.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-012101","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761920012101/doc1.xml","form_type":"4"}},{"id":3197595,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-23T21:29:07.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest and become exercisable on the one-year anniversary of the grant date, subject to continued service as a director through such date."}],"balance_after":15000,"derivative":{"exercise_price":2,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-006907","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000156761920006907/doc1.xml","form_type":"4"}},{"id":3310857,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:33:13.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":16200,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-20-003432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003432/doc4.xml","form_type":"4"}},{"id":3310856,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:33:13.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-003432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003432/doc4.xml","form_type":"4"}},{"id":3310855,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:33:13.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Reflects the correct exercise price of this option.  The exercise price of this option was previously reported as $26.01."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.15,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-003432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003432/doc4.xml","form_type":"4"}},{"id":3310854,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:33:13.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.03,"expiration_date":"2026-08-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-003432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003432/doc4.xml","form_type":"4"}},{"id":3310853,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:33:13.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":33635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.4988,"expiration_date":"2025-12-26","underlying":"Common Stock","underlying_shares":33635},"source":{"system":"sec-edgar","filing":"0001209191-20-003432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003432/doc4.xml","form_type":"4"}},{"id":3334931,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-20T00:09:16.000Z","date":"2019-09-24","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":1250,"derivative":{"exercise_price":9.15,"expiration_date":"2029-09-23","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001567619-19-023459","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000156761919023459/doc1.xml","form_type":"4"}},{"id":3479724,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T20:06:28.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.61,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000089924319017919/doc4.xml","form_type":"4"}},{"id":3482137,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T16:04:08.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":4800,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-19-017620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319017620/doc4.xml","form_type":"4"}},{"id":3482136,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:04:08.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":7500,"derivative":{"exercise_price":56.3,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-19-017620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319017620/doc4.xml","form_type":"4"}},{"id":3668144,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T17:23:31.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":16200,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-19-008669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008669/doc4.xml","form_type":"4"}},{"id":3883791,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T20:05:59.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":12.5,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-017915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000089924318017915/doc4.xml","form_type":"4"}},{"id":3884693,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T18:17:16.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":42.25,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-017760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924318017760/doc4.xml","form_type":"4"}},{"id":3900050,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T17:22:19.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2019 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-036739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118036739/doc4.xml","form_type":"4"}},{"id":4189140,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-10-10T18:05:02.000Z","date":"2017-10-08","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":9000,"derivative":{"exercise_price":26.01,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-056527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117056527/doc4.xml","form_type":"4"}},{"id":4274215,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-22T21:51:49.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":28.45,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-17-017001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924317017001/doc4.xml","form_type":"4"}},{"id":4286680,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-09T20:05:19.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":9.7,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-17-015929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626971/000089924317015929/doc4.xml","form_type":"4"}}]}